Dirucotide

Overview

Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

Background

Indication

For the treatment of multiple sclerosis (MS).

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study for Patients With Multiple Sclerosis	2009/03/27	NCT00870155	Phase 2	Terminated	Eli Lilly and Company
A Study for Patients With Secondary Progressive Multiple Sclerosis	2009/03/26	NCT00869726	Phase 2	Completed	Eli Lilly and Company
A Study for Patients With Relapsing Remitting Multiple Sclerosis	2009/03/26	NCT00869986	Phase 2	Completed	Eli Lilly and Company
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis	2007/05/03	NCT00468611	Phase 3	Terminated	BioMS Technology Corp.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

No news found

AI-Powered Research

Premium Access